CARMA3 Deficiency Abrogates G-protein-coupled Receptor Induced NF-κB Activation

Brian C. Grabiner,Marzenna Blonska,Pei-Chun Lin,Yun You,Donghai Wang,Jingbo Sun,Chen Dong,Xin Lin
IF: 11.2
2007-01-01
Cancer Research
Abstract:4158 G-protein-coupled receptors (GPCRs) represent the largest protein family in the human genome, and are involved in many cellular processes such as migration, proliferation, and invasion. GPCRs induce biological effects through the association of their cytoplasmic domains with trimeric G proteins that activate multiple signaling cascades, leading to the activation of various transcription factors including NF-κB. NF-κB is a family of transcription factors that play a pivotal role in regulating gene expression of many cytokines and survival factors. However, the molecular mechanism by which GPCRs induce NF-κB activation has not been fully characterized. Here we demonstrate that CARMA3 (Caspase recruitment domain and membrane associated guanylate kinase domain-containing protein 3), a scaffold molecule, is essential for GPCR-induced NF-κB activation. Using a gene-targeting approach, we generated CARMA3-deficient mice. We found that CARMA3-deficient mice exhibit a neural tube closure defect with incomplete penetrance, similar to that of a CARMA3-binding partner, Bcl10 (B-cell lymphoma protein 10). Using CARMA3-deficient cells, we show that the GPCR-ligands LPA (lysophosphatidic acid), ET-1 (endothelin-1), and 5-HT (serotonin) all signal through CARMA3 to activate NF-κB. Furthermore, 12-phorbol-myristate-13-acetate (PMA) and ionomycin (Iono.), two synthetic protein kinase C (PKC) agonists, also fail to activate NF-κB in CARMA3-deficient cells. Finally, our results indicate that this NF-κB activation defect is not due to an absence of phosphorylation of the inhibitor of NF-κB kinases (IKK) α and β. Instead, this defect is likely due deficient ubiquitination of the NF-κB-essential modulator (NEMO). Thus, we have provided the first genetic evidence that CARMA3 plays an essential role downstream of GPCRs and PKC to regulate NEMO ubiquitination, ultimately leading to NF-κB activation.
What problem does this paper attempt to address?